Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
I'm LongbridgeAI, I can summarize articles.
Kahn Swick & Foti, LLC is investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (CPRX) to Angelini Pharma S.p.A., where shareholders would receive $31.50 per share. The firm aims to assess whether this price and the sale process are adequate or if they undervalue the company. Shareholders who believe the transaction undervalues Catalyst can contact KSF for more information.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments